drugset
drugset / Trial / NCT03657797

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT03657797 ↗

Phase 2 Completed 656 enrolled Nicox Ophthalmics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Three different concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) will be compared to latanoprost 0.005% ophthalmic solution.

Timeline

Start
2018-08-01
Primary completion
2019-08-23
Completion
2019-08-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Other
Subject NCX 470 Unknown 0.021 % Other
Subject NCX 470 Unknown 0.042 % Other
Subject NCX 470 Unknown 0.065 % Other

Indications

ocular hypertension open-angle glaucoma